Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma

Cancer Investigation

Volumn 30, Issue 10, 2012, Pages 698-702

  Connolly, Gregory C ^a   Safadjou, Saman ^b   Chen, Rui ^b   Nduaguba, Afamefuna ^a   Dunne, Richard ^a   Khorana, Alok A ^a   Hezel, Aram F ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Liver and biliary system cancer; Outcomes research; Prognosis and response predictions

Indexed keywords

ADULT; AGED; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; REVIEW;

AGED; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84870680848     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.732162     Document Type: Review

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, FormanD.Global cancer statistics. CA: A Cancer J Clinic 2011;61(2): 69-90.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9): 1485-1491.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Intern Med 2003;139(10): 817-823.
4. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99(24): 15584-15589.
5. El-Serag HB,Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10): 745-750.
6. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk W, McLaughlin JK, Fraumeni JF. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88(20): 1472-1477.
7. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.[see comment]. Hepatology 2006;43(6): 1295-1302.
8. Wideroff L,Gridley G,Mellemkjaer L, ChowWH, LinetM, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a populationbased cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89(18): 1360-1365.
9. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrin 2011;7(8): 456-465.
10. Adams LA. Mortality in nonalcoholic fatty liver disease: clues from the Cremona study. Hepatology 2011;54(1): 6-8.
11. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17(6): 677-681.
12. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006;40(1): 68-76.
13. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis.Hepatology 1994;20(1 Pt 1): 119-125.
14. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54(4): 533-539.
15. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001;96(8): 2462-2467.
16. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetesmellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92(13): 1096-1099.
17. Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY, Lee SD. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment.. Am J Gastroenterol 2004;99(8): 1479-1487.
18. Ikeda Y, Shimada M,Hasegawa H,Gion T, Kajiyama K, Shirabe K, Yanaga K, Takenaka K, Sugimachi K. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998;27(6): 1567-1571.
19. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007;102(9): 1939-1946.
20. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Tanikawa M, Sone Y,Hisanaga Y. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer, 2001;91(5): 957-963.
21. Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, Khorana A. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008;122(3): 299-306.
22. Zhou XH, Qiao Q, Zethelius B, Pyorala K, Soderberg S, Pajak A, Stehouwer CD, Heine RJ, Jousilahti P, Ruotolo G, Nilsson PM, Calori G, Tuomilehto J. Diabetes, prediabetes and cancer mortality. Diabetologia 2010;53(9): 1867-1876.
23. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128(3): 635-643.
24. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, 3rd, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21(3): 433-440.
25. Varlotto J.M., Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 2009;115(5): 1059-1069.
26. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285(7): 885-892.
27. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 2006;42(8): 1077-1082.
28. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 2008;53(9): 2486-2494.
29. Qi HL, Zhang Y, Ma J, Guo P, Zhang XY, Chen HL. Insulin/protein kinase B signalling pathway upregulates metastasisrelated phenotypes and molecules in H7721 human hepatocarcinoma cell line. Eur J Biochem 2003;270(18): 3795-3805.
30. Yao WF, Liu JW, Sheng GL, Huang DS. Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma. Mol Med Rep 2011;4(4): 719-722.
31. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F,Housset C, Rosmorduc O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009;15(17): 5445-5456.
32. Chen YW, Boyartchuk V, Lewis BC. Differential roles of insulinlike growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia, 2009;11(9): 835-845.
33. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.World J Gastroenterol, 2008;14(37): 5695-5700.
34. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol, 2009;15(3): 280-288.